Cardiac troponin identifies immune checkpoint inhibitor associated myocarditis and stratifies cardiovascular risk a systematic review and meta analysis
Clicks: 1
ID: 323278
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #226 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Immune checkpoint inhibitors are associated with myocarditis, a rare but potentially life-threatening immune-related adverse event. Cardiac troponin is widely used in clinical practice; however, its diagnostic performance for immune checkpoint inhibitor–associated myocarditis and its prognostic value for subsequent cardiovascular outcomes have not been systematically quantified. Purpose To address two complementary objectives: (1) to evaluate the diagnostic performance of troponin elevation for immune checkpoint inhibitor–associated myocarditis, and (2) to assess the prognostic association between troponin elevation and major adverse cardiovascular events and mortality in adults receiving immune checkpoint inhibitor therapy. Methods We conducted a PRISMA-compliant systematic review and meta-analysis of MEDLINE, Embase, CENTRAL, and Scopus from inception to October 2025. Diagnostic studies evaluated troponin elevation against established myocarditis reference standards. Prognostic studies assessed associations between troponin elevation and time-to-event outcomes, including major adverse cardiovascular events and mortality. Effect estimates were pooled using random-effects models. Results Twenty-four studies comprising 7,258 patients were included. Across diagnostic studies (n=4; 1,051 patients), troponin elevation above assay-specific thresholds was strongly associated with confirmed immune checkpoint inhibitor–associated myocarditis (pooled log odds ratio 4.14, 95% confidence interval 2.80–5.48; I²=0%). In prognostic analyses, troponin elevation was associated with a significantly increased risk of major adverse cardiovascular events (pooled hazard ratio 6.14, 95% confidence interval 3.61–10.45) and with increased mortality (pooled hazard ratio 1.95, 95% confidence interval 1.36–2.81). Studies reporting higher or persistent troponin elevations demonstrated greater cardiovascular risk. Conclusions Troponin elevation in patients receiving immune checkpoint inhibitors identifies myocardial injury and provides clinically relevant risk stratification for adverse cardiovascular outcomes. While troponin demonstrates high sensitivity for immune checkpoint inhibitor–associated myocarditis and prognostic value for subsequent events, variability in assays and thresholds limits its specificity as a standalone diagnostic test, underscoring the need for integrated clinical assessment.Diagnostic Performance Forest Plot MACE/CV Events Forest Plot
| Reference Key |
openalex_W7172273237
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | A Alfehaid, A Alaraibi, M Alani, L Alnooh, N Quateen, L Alqallaf, R Alazemi, M Taqi, P Murray |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.132
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.